2.50
Hdl Handle:
http://hdl.handle.net/10541/99237
Title:
VAD chemotherapy as remission induction for multiple myeloma.
Authors:
Anderson, Heather; Scarffe, J Howard; Ranson, Malcolm R; Young, R; Wieringa, Gilbert E; Morgenstern, Godfrey R; Fitzsimmons, Lesley; Ryder, W David J
Abstract:
A total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In addition, oral dexamethasone 40 mg day-1 was given for 4 days. Intermittent dexamethasone was only given to 19 patients. Courses were repeated every 21 days. The overall response rate was 84% [27% complete response (CR)] in previously untreated patients and 61% (3% CR) in patients with relapsed and refractory disease. The median survival was 36 months for untreated patients and 10 months for those who had received prior therapy. VAD was well tolerated; however, despite prophylaxis, 54% patients received antibiotics at some time during therapy and 37% had dyspepsia. Twenty-three patients subsequently received a transplant (eight allografts, eight marrow autografts and seven peripheral blood stem cell transplants). Eight have died-four in the allogeneic group and four in the autologous group. The overall median survival of transplanted patients has not yet been reached. VAD is an effective, out-patient therapy for inducing remission in multiple myeloma. Post-remission therapy needs to be optimised, but it is likely that the needs of previously untreated patients may be different from those with relapsed and refractory disease.
Affiliation:
Department of Medical Oncology, Christie Hospital, Manchester, UK.
Citation:
VAD chemotherapy as remission induction for multiple myeloma. 1995, 71 (2):326-30 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Feb-1995
URI:
http://hdl.handle.net/10541/99237
PubMed ID:
7841049
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorYoung, Ren
dc.contributor.authorWieringa, Gilbert Een
dc.contributor.authorMorgenstern, Godfrey Ren
dc.contributor.authorFitzsimmons, Lesleyen
dc.contributor.authorRyder, W David Jen
dc.date.accessioned2010-05-19T09:55:23Z-
dc.date.available2010-05-19T09:55:23Z-
dc.date.issued1995-02-
dc.identifier.citationVAD chemotherapy as remission induction for multiple myeloma. 1995, 71 (2):326-30 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid7841049-
dc.identifier.urihttp://hdl.handle.net/10541/99237-
dc.description.abstractA total of 142 patients with multiple myeloma received VAD as remission induction therapy. Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total dose 1.6 mg) was infused with doxorubicin 36 mg m-2 by continuous ambulatory pump over 4 days. In addition, oral dexamethasone 40 mg day-1 was given for 4 days. Intermittent dexamethasone was only given to 19 patients. Courses were repeated every 21 days. The overall response rate was 84% [27% complete response (CR)] in previously untreated patients and 61% (3% CR) in patients with relapsed and refractory disease. The median survival was 36 months for untreated patients and 10 months for those who had received prior therapy. VAD was well tolerated; however, despite prophylaxis, 54% patients received antibiotics at some time during therapy and 37% had dyspepsia. Twenty-three patients subsequently received a transplant (eight allografts, eight marrow autografts and seven peripheral blood stem cell transplants). Eight have died-four in the allogeneic group and four in the autologous group. The overall median survival of transplanted patients has not yet been reached. VAD is an effective, out-patient therapy for inducing remission in multiple myeloma. Post-remission therapy needs to be optimised, but it is likely that the needs of previously untreated patients may be different from those with relapsed and refractory disease.en
dc.language.isoenen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshDexamethasone-
dc.subject.meshDoxorubicin-
dc.subject.meshFemale-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshMultiple Myeloma-
dc.subject.meshRemission Induction-
dc.subject.meshSurvival Analysis-
dc.subject.meshVincristine-
dc.titleVAD chemotherapy as remission induction for multiple myeloma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.